Myokardia Inc.

5 trials Commercial sponsor

Filter these 5 trials by condition, phase, country and more.

Open in Search →

5 Registered trials

0 Recruiting

6 Completed trials

15 Countries active

3 Unique IMPs

100% Results reported

Phase III

Phase II

Phase III/IV

Phase III: 2 Phase II: 2 Phase III/IV: 1

Oversight events:

1 serious breach across 1 trial

View oversight register →

100%

6 of 6 completed trials have published summary results (EU CTR Article 37 — 12-month obligation).

View full Transparency Scoreboard →

Top indications

Hypertrophic cardiomyopathy 3 Non-obstructive cardiomyopathy 1

Top IMPs

MAVACAMTEN 3 BMS-986435 1 DANICAMTIV 1

All trials

5 total

A Randomized, Double-blind, Placebo-controlled Clinical Study to Evaluate Mavacamten in Adults with Cardiomyopathy Ended

2023-506352-24-00 Phase III 13 countries MAVACAMTEN
Multiple Dose Study to Evaluate Efficacy, Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of MYK-224 in Participants with Sympto… Ended

2023-508831-29-00 Phase II 3 countries BMS-986435
Heart Failure study with Danicamtiv in patients with reduced heart function caused by gene mutation Ended

2023-505492-68-00 Phase II 2 countries DANICAMTIV
A Long-term Safety Extension Study of Mavacamten (MYK-461) in Adults with Hypertrophic Cardiomyopathy Who Have Completed the MAVERICKHCM (MY… Ended

2022-502858-14-00 Phase III 10 countries MAVACAMTEN
Mavacamten Impact on Myocardial Structure in Obstructive Hypertrophic Cardiomyopathy Ended

2022-502316-36-00 Phase III/IV 11 countries MAVACAMTEN

Showing 1–5 of 5 trials

← All sponsors A–Z